Association of ki67 and tumor marker p53 in locally advanced breast cancer patients and evaluation of response to neoadjuvant chemotherapy: a survey in South Iran

References

• Vaidya JS, Massarut S, Vaidya HJ, et al. Rethinking neoadjuvant chemotherapy for breast cancer. BMJ. 2018;360:j5913. doi:10.1136/bmj.j591329326104
   PubMedGoogle Scholar
• Li X, Krishnamurti U, Bhattarai S, et al. Biomarkers predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer. Am J Clin Pathol. 2016;145(6):871–878. doi:10.1093/ajcp/aqw04527298399
   PubMed Web of Science ®Google Scholar
• Vila J, Mittendorf EA, Farante G, et al. Nomograms for predicting axillary response to neoadjuvant chemotherapy in clinically node-positive patients with breast cancer. Ann Surg Oncol. 2016;23(11):3501–3509. doi:10.1245/s10434-016-5277-127216742
   PubMed Web of Science ®Google Scholar
• Pennisi A, Kieber-Emmons T, Makhoul I, Hutchins L. Relevance of pathological complete response after neoadjuvant therapy for breast cancer. Breast Cancer. 2016;10(BCBCR):S33163. doi:10.4137/BCBCR.S33163
   Google Scholar
• von Minckwitz G, Blohmer JU, Costa SD, et al. Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol. 2013;31(29):3623–3630. doi:10.1200/JCO.2012.45.094024002511
   PubMed Web of Science ®Google Scholar
• Von Minckwitz G, Blohmer J, Costa S, et al. Neoadjuvant chemotherapy adapted by interim response improves overall survival of primary breast cancer patients–results of the gepartrio trial. AACR. 2011;(71)(24 Supplement):S3-2.
   Google Scholar
• Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–172. doi:10.1016/S0140-6736(13)62422-824529560
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Untch M, Blohmer J-U, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–1804. doi:10.1200/JCO.2011.38.859522508812
   PubMed Web of Science ®Google Scholar
• Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105–113. doi:10.1200/JCO.2009.23.737019917869
   PubMed Web of Science ®Google Scholar
• Giuliano AE, Connolly JL, Edge SB, et al. Breast cancer—major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(4):290–303. doi:10.3322/caac.2139328294295
   PubMed Web of Science ®Google Scholar
• Bhargava R, Beriwal S, Dabbs DJ, et al. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases. Cancer Interdiscip Int J Am Cancer Soc. 2010;116(6):1431–1439. doi:10.1002/cncr.24876
   Google Scholar
• Sueta A, Yamamoto Y, Hayashi M, et al. Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer; is it equally useful across tumor subtypes? Surgery. 2014;155(5):927–935. doi:10.1016/j.surg.2014.01.00924582496
   PubMed Web of Science ®Google Scholar
• Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329–2334. doi:10.1158/1078-0432.CCR-06-110917438091
   PubMed Web of Science ®Google Scholar
• Yoshioka T, Hosoda M, Yamamoto M, et al. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer. Breast Cancer. 2015;22(2):185–191. doi:10.1007/s12282-013-0474-223645542
   PubMed Web of Science ®Google Scholar
• Kim T, Han W, Kim MK, et al. Predictive significance of p53, Ki-67, and Bcl-2 expression for pathologic complete response after neoadjuvant chemotherapy for triple-negative breast cancer. J Breast Cancer. 2015;18(1):16–21. doi:10.4048/jbc.2015.18.1.1625834606
   PubMed Web of Science ®Google Scholar
• Kim KI, Lee KH, Kim TR, Chun YS, Lee TH, Park HK. Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer. 2014;17(1):40–46. doi:10.4048/jbc.2014.17.1.4024744796
   PubMed Web of Science ®Google Scholar
• Dowsett M, Nielsen TO, A’hern R, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst. 2011;103(22):1656–1664. doi:10.1093/jnci/djr39321960707
   PubMed Web of Science ®Google Scholar
• Tang P, Tse GM. Immunohistochemical surrogates for molecular classification of breast carcinoma: a 2015 update. Arch Pathol Lab Med. 2016;140(8):806–814. doi:10.5858/arpa.2015-0133-RA27472239
   PubMed Web of Science ®Google Scholar
• Lee DS, Kim SH, Kim S, Suh YJ, Kim HK, Shim BY. Prognostic significance of breast cancer subtype and p53 overexpression in patients with locally advanced or high-risk breast cancer treated using upfront modified radical mastectomy with or without post-mastectomy radiation therapy. Int J Clin Oncol. 2012;17(5):447–455. doi:10.1007/s10147-011-0309-021898181
   PubMed Web of Science ®Google Scholar
• Lee D-S, Kim SH, Suh YJ, Kim S, Kim HK, Shim BY. Clinical implication of p53 overexpression in breast cancer patients younger than 50 years with a triple-negative subtype who undergo a modified radical mastectomy. Jpn J Clin Oncol. 2011;41(7):854–866. doi:10.1093/jjco/hyr06621719749
   PubMed Web of Science ®Google Scholar
• Bertheau P, Lehmann-Che J, Varna M, et al. p53 in breast cancer subtypes and new insights into response to chemotherapy. Breast. 2013;22:S27–S29. doi:10.1016/j.breast.2013.07.00524074787
   PubMed Web of Science ®Google Scholar
• Carlson RW, Allred DC, Anderson BO, et al. Breast cancer. JNCCN. 2009;7(2):122–19219200416
   PubMedGoogle Scholar
• World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191. doi:10.1001/jama.2013.28105324141714
   PubMed Web of Science ®Google Scholar
• Lee HJ, Seo J-Y, Ahn J-H, Ahn S-H, Gong G. Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer. 2013;16(1):32–39. doi:10.4048/jbc.2013.16.1.3223593079
   PubMed Web of Science ®Google Scholar
• Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40–50. doi:10.1016/S1470-2045(17)30904-X29233559
   PubMed Web of Science ®Google Scholar
• Hammond MEH, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48–e72.20586616
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2013;138(2):241–256. doi:10.5858/arpa.2013-0953-SA24099077
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Winer EP, Coates A, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–2223. doi:10.1093/annonc/mdt30323917950
   PubMed Web of Science ®Google Scholar
• Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414–4422. doi:10.1200/JCO.2007.10.682317785706
   PubMed Web of Science ®Google Scholar
• Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003;12(5):320–327.14659147
   PubMed Web of Science ®Google Scholar
• Payandeh M, Sadeghi M, Sadeghi E, Madani S-H. Expression of p53 breast cancer in Kurdish women in the West of Iran: a reverse correlation with lymph node metastasis. Asian Pac J Cancer Prev. 2016;17(3):1261–1264.27039757
   PubMedGoogle Scholar
• Errahhali ME, Errahhali ME, Ouarzane M, El Harroudi T, Afqir S, Bellaoui M. First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: series of 2260 cases. BMC Women’s Health. 2017;17(1):3. doi:10.1186/s12905-016-0361-z28068979
   PubMedGoogle Scholar
• Kohler BA, Sherman RL, Howlader N, et al. Annual report to the nation on the status of cancer, 1975–2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. JNCI. 2015;107(6). doi:10.1093/jnci/djv048
   PubMedGoogle Scholar
• Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012;48(18):3342–3354. doi:10.1016/j.ejca.2012.05.02322766518
   PubMed Web of Science ®Google Scholar
• Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11(16):5678–5685. doi:10.1158/1078-0432.CCR-04-242116115903
   PubMed Web of Science ®Google Scholar
• Mathieu M-C, Rouzier R, Llombart-Cussac A, et al. The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer. 2004;40(3):342–351.14746851
   PubMed Web of Science ®Google Scholar
• Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci. 2001;98(19):10869–10874. doi:10.1186/1471-2407-11-48611553815
   PubMed Web of Science ®Google Scholar
• Shokouh TZ, Ezatollah A, Barand P. Interrelationships between Ki67, HER2/neu, p53, ER, and PR status and their associations with tumor grade and lymph node involvement in breast carcinoma subtypes: retrospective-observational analytical study. Medicine. 2015;94:32. doi:10.1097/MD.0000000000000874
   Web of Science ®Google Scholar
• Fasching PA, Heusinger K, Haeberle L, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer. 2011;11(1):486. doi:10.1186/1471-2407-11-48622081974
   PubMedGoogle Scholar
• Denkert C, Loibl S, Müller B, et al. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial. Annals of Oncology. 2013;24(11):2786–2793. doi:10.1093/annonc/mdt35023970015
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Sinn H-P, Raab G, et al. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res. 2008;10(2):R30. doi:10.1186/bcr198918380893
   PubMed Web of Science ®Google Scholar
• Payandeh M, Malayeri R, Sadeghi M, Sadeghi E, Gholami F. Expression of p53 and Ki67 in the patients with triple negative breast cancer and invasive ductal carcinoma. Am J Cancer Prev. 2015;3:58–61.
   Google Scholar
• Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 2008;9(5):402. doi:10.1038/nrm239518431400
   PubMed Web of Science ®Google Scholar
• Mao Y, Qu Q, Zhang Y, Liu J, Chen X, Shen K. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS One. 2014;9(12):e115103. doi:10.1371/journal.pone.011510325501357
   PubMed Web of Science ®Google Scholar
• Loi S, Michiels S, Salgado R, et al. Abstract S1-05: tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC). Cancer Res. 2013;73(24 Suppl):S1–05.
   Google Scholar
• Ono M, Tsuda H, Shimizu C, et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2012;132(3):793–805. doi:10.1007/s10549-011-1554-721562709
   PubMed Web of Science ®Google Scholar
• West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011;13(6):R126. doi:10.1186/bcr305222151962
   PubMed Web of Science ®Google Scholar
• Hwang HW, Jung H, Hyeon J, et al. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients. Breast Cancer Res Treat. 2019;173(2):255–266.
   Web of Science ®Google Scholar